A biopharma supplier undertakes a supply chain risk analysis to demonstrate its rigorous approach to client fulfilment

A supplier to major biopharmaceutical companies was identified as the sole source of certain biopharma materials. Consequently, one of these companies required evidence of the supplier’s supply chain risk analysis, as part of a due diligence exercise.

Furthermore, the supplier was coming under pressure internally from the finance team to reduce working capital in the form of safety stock. However, the supply chain leads were concerned about the message this would send about the resilience of their supply chains to customers.